Smith & Nephew (SN) Stock Rating Lowered by Deutsche Bank

Smith & Nephew (LON:SN) was downgraded by Deutsche Bank to a “sell” rating in a note issued to investors on Friday, May 4th.

A number of other research firms have also commented on SN. JPMorgan Chase reissued an “overweight” rating on shares of Smith & Nephew in a research report on Wednesday, April 25th. Credit Suisse Group reissued a “neutral” rating and issued a GBX 1,290 ($17.50) price target on shares of Smith & Nephew in a research report on Tuesday, April 24th. Jefferies Group reissued a “buy” rating on shares of Smith & Nephew in a research report on Thursday, April 12th. HSBC raised shares of Smith & Nephew to a “buy” rating and lifted their price target for the company from GBX 1,320 ($17.91) to GBX 1,530 ($20.75) in a research report on Monday, March 26th. Finally, Morgan Stanley dropped their price target on shares of Smith & Nephew from GBX 1,558 ($21.13) to GBX 1,457 ($19.76) and set an “equal weight” rating on the stock in a research report on Tuesday, February 13th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. Smith & Nephew presently has a consensus rating of “Hold” and an average target price of GBX 1,387.68 ($18.82).

Smith & Nephew opened at GBX 1,326 ($17.99) on Friday, MarketBeat reports. Smith & Nephew has a 12 month low of GBX 1,173 ($15.91) and a 12 month high of GBX 1,442 ($19.56).

In related news, insider Graham Baker acquired 1,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were acquired at an average price of GBX 1,283 ($17.40) per share, for a total transaction of £12,830 ($17,403.69). Also, insider Olivier Bohuon sold 8,171 shares of the firm’s stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of GBX 1,301 ($17.65), for a total transaction of £106,304.71 ($144,200.64).

About Smith & Nephew

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply